Cory Wiegert named CEO of CancerLinQ LLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cory Wiegert was named chief executive officer of CancerLinQ LLC, a non-profit subsidiary of the American Society of Clinical Oncology.

Wiegert most recently served as vice president of product management for IBM Watson Health. He led the launch of major projects, including IBM’s first cloud-based offerings in healthcare and the creation of new solutions from the integration of several major acquisitions.

Prior to joining IBM, Wiegert held positions with Sterling Commerce, Siebel Systems, Inc., Centura Software Corporation, and Safety-Kleen.

CancerLinQ is a big data initiative that collects and analyzes data fromcancer patients at practices nationwide, drawing from electronic health records, to inform and improve the quality of cancer care. The effort has two major components: 1) the CancerLinQ quality improvement and data-sharing platform for oncology practices, and 2) CancerLinQ Discovery, which provides access to high-quality, de-identified datasets derived from the patient data to academic researchers, non-profit organizations, government agencies, industry, and others in the oncology community.

The CancerLinQ database contains more than a million cancer patient records, making it one of the largest and most comprehensive data sets of its kind. In addition, CancerLinQ LLC has established a number of collaborations with government and nonprofit entities—including American Society of Radiation Oncology, FDA, and NCI—as well as industry through its collaborators AstraZeneca, Tempus, and Concerto HealthAI.

Wiegert replaces Richard Schilsky, who was serving as interim CEO of CancerLinQ. Schilsky will continue his role as ASCO’s chief medical officer.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login